Precision Medicine in breast cancer

Precision medicine in breast cancer: Data4Cure’s platform used in research published in JNNC

Data4Cure’s Biomedical Intelligence Platform has been used in a research published in the Journal of the National Comprehensive Cancer Network in February 2016.

The article describes the Intensive Trial of OMics in Cancer (ITOMIC), a novel approach to clinical research that brought together 32 researchers from 14 different institutions with a goal to identify potential treatments for a patient with metastatic triple-negative breast cancer (TNBC)—an especially aggressive subset of breast cancer.

Data4Cure’s Biomedical Intelligence Platform has been used to analyze the data.

cancer bioinformatics precision medicine
A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. Source: Journal of the National Comprehensive Cancer Network

ITOMIC, led by C. Anthony Blau, MD, Director of the Center for Cancer Innovation and Professor of Medicine, Division of Hematology, University of Washington School of Medicine in Seattle, is an attempt to bring molecular and precision medicine from bench to bedside. Bioinformatics and genomics data analysis is a critical part of this.

ITOMIC aims to characterize and track the molecular features of a tumor, aggregate experts to generate interventions hypotheses, test them in the patient, and learn from these experiences.

“On a molecular level, every cancer is unique,” said Dr. Blau in the press release. “By breaking down institutional barriers, this collaborative study brings a ‘no-holds-barred’ effort to trying to help an individual cancer patient using tools that virtually unite experts from around the world.”

To read the article, please visit the JNCCN website. The publication is cited below.

Citation:

Blau CA, Ramirez AB, Blau S, Pritchard CC, Dorschner MO, Schmechel SC, Martins TJ, Mahen EM, Burton KA, Komashko VM, Radenbaugh AJ, Dougherty K, Thomas A, Miller CP, Annis J, Fromm JR, Song C, Chang E, Howard K, Austin S, Schmidt RA, Linenberger ML, Becker PS, Senecal FM, Mecham BH, Lee SI, Madan A, Ronen R, Dutkowski J, Heimfeld S, Wood BL, Stilwell JL, Kaldjian EP, Haussler D, Zhu J. A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. J Natl Compr Canc Netw. 2016 Jan;14(1):8-17.

Learn more about:

The University of Washington features one of the most highly regarded medical schools in the world and its  Medical Center now ranked by U.S. News and World Report among the top ten hospitals in the United States.

The Journal of the National Comprehensive Cancer Network is the official journal of the National Comprehensive Cancer Network (NCCN).More than 23,000 oncologists and other cancer care professionals across the United States read JNCCN. It publishes the NCCN Clinical Practice Guidelines in Oncology, updates and review articles elaborating on guideline recommendations, and health services and clinical research papers, as well as correspondence and commentaries.

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 27 of the world’s leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Precision Medicine in Breast Cancer
Precision Medicine in Breast Cancer. A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. Source: JNNC